Human Adaptation of Ebola Virus during the West African Outbreak
Cell November 3, 2016 V.167 N.4 1079-1087
Richard A. Urbanowicz, C. Patrick McClure, Anavaj Sakuntabhai, Amadou A. Sall, Gary Kobinger13,14, Marcel A. Müller, Edward C. Holmes, Félix A. Rey, Etienne Simon-Loriere, Jonathan K. Ball
Present address: Département de microbiologie-infectiologie et d’immunologie, Université Laval, QC G1V 0A6, Canada
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- EBOV adapted to humans during the West African outbreak
- Amino acid substitutions in the EBOV glycoprotein increase human cell tropism
- The same glycoprotein amino acid substitutions decrease tropism for bat cells
The 2013–2016 outbreak of Ebola virus (EBOV) in West Africa was the largest recorded. It began following the cross-species transmission of EBOV from an animal reservoir, most likely bats, into humans, with phylogenetic analysis revealing the co-circulation of several viral lineages. We hypothesized that this prolonged human circulation led to genomic changes that increased viral transmissibility in humans. We generated a synthetic glycoprotein (GP) construct based on the earliest reported isolate and introduced amino acid substitutions that defined viral lineages. Mutant GPs were used to generate a panel of pseudoviruses, which were used to infect different human and bat cell lines. These data revealed that specific amino acid substitutions in the EBOV GP have increased tropism for human cells, while reducing tropism for bat cells. Such increased infectivity may have enhanced the ability of EBOV to transmit among humans and contributed to the wide geographic distribution of some viral lineages.
Entry filed under: Biología Molecular, Epidemiología, FIEBRE en el POST-VIAJE, FIEBRE y RASH, Infecciones emergentes, Infecciones virales, Medicina del viajero, Metodos diagnosticos, REPORTS, Sepsis, Update, Zoonosis.
Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013–2016 Epidemic Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016